AAN, 21-27 April 2018, Los Angeles
Welcome to Roche at AAN 2018
The Annual Meeting of the American Academy of Neurology brings together neurology experts from around the world to discuss the latest advancements within their field. This year’s program includes symposia, workshops and special sessions on clinical cases.
AAN 2018 – April 21-27, Los Angeles
Discover Roche’s information from this year’s AAN on this page, including posters and an oral presentation.
Latest on Medically from AAN 2018
AAN 2018 poster: Safety and tolerability and pharmacokinetics of crenezumab in mild-to-moderate AD patients treated with escalating doses for up to 32 months
The ongoing Phase 1b study GN29632 was designed to provide information on the safety, tolerability and pharmacokinetics of crenezumab delivered at higher doses than used in the Phase 2 ABBY and BLAZE studies, and to support the Phase 3 studies. The study enrolled patients with probable mild-to moderate AD per NINCDS-ADRDA criteria. Updated safety data for patients who have received crenezumab for up to 32 months, and pooled PK and PD data from this study plus ABBY and BLAZE are presented.
AAN 2018 poster: Characterization of the Selective In Vivo and In Vitro Binding Properties of Crenezumab: Insights into Crenezumab’s Unique Mechanism of Action
Crenezumab is a monoclonal anti-Aβ immunoglobulin G4 (IgG4) antibody being developed for the treatment of AD. In this study, we characterized the in vivo binding pattern of crenezumab to Aβ in brains of PS2APP mice by immunohistochemistry and electron microscopy following a single intravenous injection. Using immunoprecipitation and Western blotting, we also evaluated the interaction between crenezumab and different forms of synthetic or native Aβ.
AAN 2018 oral presentation: Higher Dose Gantenerumab leads to Significant Reduction in Amyloid Plaque Burden: Results for the Marguerite and Scarlet Road Open Label Extension Studies
Gantenerumab is a fully human monoclonal antibody currently under evaluation at titrated doses up to 1200 mg sc monthly in the Scarlet RoAD (SR, NCT01224106) and Marguerite RoAD (MR, NCT02051608) open label extension (OLE) studies. Here we report amyloid burden using alternative SUVR methods (template-space and native-space Freesurfer), and relate amyloid reductions to factors including baseline SUVR and dosing schedules.
AAN 2018 poster: Optimizing the gantenerumab phase 3 dosing regimen through PK-PD modeling and clinical trial simulations
The key objective of this work was to determine a safe, potentially efficacious and simple dosing regimen for both ApoEε4 carriers and non-carriers. Mathematical PK-PD models for PET (surrogate for efficacy) and ARIA (safety) were developed to establish an optimal gantenerumab dosing regimen. Combining retrospective internal and external data as well as new data from the open label studies, updated PK-PD models were used to simulate different titration regimens.